| Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology MB Daly, T Pal, MP Berry, SS Buys, P Dickson, SM Domchek, ... Journal of the National Comprehensive Cancer Network 19 (1), 77-102, 2021 | 635 | 2021 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines MB Daly, R Pilarski, MB Yurgelun, MP Berry, SS Buys, P Dickson, ... Journal of the National Comprehensive Cancer Network 18 (4), 380-391, 2020 | 358 | 2020 |
| Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I E Kakkis, M McEntee, C Vogler, S Le, B Levy, P Belichenko, W Mobley, ... Molecular genetics and metabolism 83 (1-2), 163-174, 2004 | 223 | 2004 |
| Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid P Dickson, M McEntee, C Vogler, S Le, B Levy, M Peinovich, S Hanson, ... Molecular genetics and metabolism 91 (1), 61-68, 2007 | 195 | 2007 |
| Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression MV Munoz‐Rojas, T Vieira, R Costa, S Fagondes, A John, LB Jardim, ... American journal of medical genetics Part A 146 (19), 2538-2544, 2008 | 170 | 2008 |
| Intrathecal delivery of protein therapeutics to the brain: a critical reassessment P Calias, WA Banks, D Begley, M Scarpa, P Dickson Pharmacology & therapeutics 144 (2), 114-122, 2014 | 167 | 2014 |
| C-type natriuretic peptide analogue therapy in children with achondroplasia R Savarirayan, M Irving, CA Bacino, B Bostwick, J Charrow, ... New England Journal of Medicine 381 (1), 25-35, 2019 | 163 | 2019 |
| Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I P Dickson, M Peinovich, M McEntee, T Lester, S Le, A Krieger, H Manuel, ... The Journal of clinical investigation 118 (8), 2868-2876, 2008 | 130 | 2008 |
| Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB S Kan, M Aoyagi-Scharber, SQ Le, J Vincelette, K Ohmi, S Bullens, ... Proceedings of the National Academy of Sciences 111 (41), 14870-14875, 2014 | 122 | 2014 |
| A qualitative study of patient education needs for hip and knee replacement D Kennedy, A Wainwright, L Pereira, S Robarts, P Dickson, J Christian, ... BMC musculoskeletal disorders 18, 1-7, 2017 | 119 | 2017 |
| Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann–Pick C1 TJ Maarup, AH Chen, FD Porter, NY Farhat, DS Ory, R Sidhu, X Jiang, ... Molecular genetics and metabolism 116 (1-2), 75-79, 2015 | 110 | 2015 |
| ETHE1 mutations are specific to ethylmalonic encephalopathy V Tiranti, E Briem, E Lamantea, R Mineri, E Papaleo, L De Gioia, F Forlani, ... Journal of medical genetics 43 (4), 340-346, 2006 | 103 | 2006 |
| IRF2BPL is associated with neurological phenotypes PC Marcogliese, V Shashi, RC Spillmann, N Stong, JA Rosenfeld, ... The American Journal of Human Genetics 103 (2), 245-260, 2018 | 97 | 2018 |
| Loss-of-function in IRF2BPL is associated with neurological phenotypes PC Marcogliese, V Shashi, RC Spillmann, N Stong, JA Rosenfeld, ... bioRxiv, 322495, 2018 | 97* | 2018 |
| Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction PS Kishnani, PI Dickson, L Muldowney, JJ Lee, A Rosenberg, ... Molecular genetics and metabolism 117 (2), 66-83, 2016 | 86 | 2016 |
| Replacing the Enzyme α-l-Iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type I AD Dierenfeld, MF McEntee, CA Vogler, CH Vite, AH Chen, M Passage, ... Science translational medicine 2 (60), 60ra89-60ra89, 2010 | 86 | 2010 |
| Glycan-based biomarkers for mucopolysaccharidoses R Lawrence, JR Brown, F Lorey, PI Dickson, BE Crawford, JD Esko Molecular genetics and metabolism 111 (2), 73-83, 2014 | 79 | 2014 |
| WITHDRAWN: Glycan-based biomarkers for mucopolysaccharidoses. R Lawrence, JR Brown, F Lorey, PI Dickson, BE Crawford, JD Esko Disease Markers, 2013 | 79 | 2013 |
| Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy RJ Holley, SM Ellison, D Fil, C O’Leary, J McDermott, N Senthivel, ... Brain 141 (1), 99-116, 2018 | 75 | 2018 |
| Treatment of brain disease in the mucopolysaccharidoses M Scarpa, PJ Orchard, A Schulz, PI Dickson, ME Haskins, ML Escolar, ... Molecular genetics and metabolism 122, 25-34, 2017 | 73 | 2017 |
